Tongue cancer natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Tongue cancer}} {{CMG}} ==Overview== ==References== {{reflist|2}}") |
Simrat Sarai (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tongue cancer}} | {{Tongue cancer}} | ||
{{CMG}} | {{CMG}}{{AE}}{{Simrat}} | ||
==Overview== | |||
==Natural History== | |||
Carcinomas of the tongue base are clinically silent until they deeply infiltrate the tongue musculature. They are usually less differentiated. Because of the difficulties with direct visualization, they may extend into the oral tongue or have clinical lymph metastases before the diagnosis is established. | |||
==Complications== | |||
==Prognosis== | |||
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | |||
Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | |||
Although the five-year overall survival for early stage oral tongue cancer reported by a single institution was quite good, 89 and 95 percent for stage I and II cancers, the five-year survival calculated from a population-based database was more modest, 67 and 51 percent, respectively [31,33]. Tongue cancer is often believed to have a more aggressive course in younger patients (ie, <40 years), but most reports have not found a difference in survival between younger and older patients. | |||
Cancer of the oral tongue has been associated with a worse prognosis compared with other oral cavity subsites in some but not all series [16,17]. Typically, five-year disease-specific survival rates of 39 and 27 percent have been achieved for stage III and IV disease, respectively [18]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:28, 19 November 2015
|
Tongue cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tongue cancer natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Tongue cancer natural history, complications and prognosis |
|
FDA on Tongue cancer natural history, complications and prognosis |
|
CDC on Tongue cancer natural history, complications and prognosis |
|
Tongue cancer natural history, complications and prognosis in the news |
|
Blogs on Tongue cancer natural history, complications and prognosis |
|
Risk calculators and risk factors for Tongue cancer natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Natural History
Carcinomas of the tongue base are clinically silent until they deeply infiltrate the tongue musculature. They are usually less differentiated. Because of the difficulties with direct visualization, they may extend into the oral tongue or have clinical lymph metastases before the diagnosis is established.
Complications
Prognosis
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
Although the five-year overall survival for early stage oral tongue cancer reported by a single institution was quite good, 89 and 95 percent for stage I and II cancers, the five-year survival calculated from a population-based database was more modest, 67 and 51 percent, respectively [31,33]. Tongue cancer is often believed to have a more aggressive course in younger patients (ie, <40 years), but most reports have not found a difference in survival between younger and older patients. Cancer of the oral tongue has been associated with a worse prognosis compared with other oral cavity subsites in some but not all series [16,17]. Typically, five-year disease-specific survival rates of 39 and 27 percent have been achieved for stage III and IV disease, respectively [18].